'+
'| • '+heading+' |
| '+
''+
' |
'); } function hiLite(imgDocID,imgObjName) { document.images[imgDocID].src = eval(imgObjName + ".src"); } function showStatus(toshow) { window.status = toshow; } function checkChoose() { if (document.choose.ticker.value == "") { alert("Please enter symbols before clicking the go button"); return false; } else return true; } function popJT(url,name){ var xwid = screen.width; xwid = xwid - 10; javaticker = window.open(url,name,'width='+xwid+',height=100,resizable=yes,scrollbars=no,toolbar=no,location=no,directories=no,status=yes,menubar=no'); javaticker.opener.name="opener"; //javaticker.moveTo(0,30); } var allow = 0; var ref = ""+location; if ((ref.indexOf("cryptocurrencieschannel.com") > 0) || (ref.indexOf("cefchannel.com") > 0) || (ref.indexOf("bdcinvestor.com") > 0) || (ref.indexOf("tickertech.com") > 0) || (ref.indexOf("xxxx:") > 0) || (ref.indexOf("javascript:") > 0) || (ref.indexOf("filseclab.com") > 0) || (ref.indexOf("msnscache.com") > 0) || (ref.indexOf("toolbar.google.com") > 0) || (ref.indexOf("etfchannel.com") > 0) || (ref.indexOf("marketnewsvideo.com") > 0) || (ref.indexOf("news.google.com") > 0) || (ref.indexOf("dividendchannel.com") > 0) || (ref.indexOf("www.google.com") > 0) || (ref.indexOf("energystockchannel.com") > 0) || (ref.indexOf("metalschannel.com") > 0) || (ref.indexOf("portfoliochannel.com") > 0) || (ref.indexOf("canadastockchannel.com") > 0) || (ref.indexOf("theonlineinvestor.com") > 0) || (ref.indexOf("investhelp.com") > 0) || (ref.indexOf("preferredstockchannel.com") > 0) || (ref.indexOf("stockoptionschannel.com") > 0) || (ref.indexOf("holdingschannel.com") > 0) || (ref.indexOf("tickertech.net") > 0) || (ref.indexOf("historicalstockprice.com") > 0) || (ref.indexOf("splithistory.com") > 0) || (ref.indexOf("stocksplithistory.com") > 0) || (ref.indexOf("google.c") > 0) || (ref.indexOf("208.71.46.190") > 0) || (ref.indexOf("search.yahoo") > 0) || (ref.indexOf("sharesoutstandinghistory.com") > 0) || (ref.indexOf("marketcaphistory.com") > 0) || (ref.indexOf("ytdreturn.com") > 0) || (ref.indexOf("averageannualreturn.com") > 0) || (ref.indexOf("redinews.com") > 0) || (ref.indexOf("technicalanalysischannel.com") > 0) || (ref.indexOf("stockdma.com") > 0) || (ref.indexOf("stockrsi.com") > 0) || (ref.indexOf("stockmacd.com") > 0) || (ref.indexOf("topdividends.com") > 0) || (ref.indexOf("monthlydividendpayingstocks.com") > 0) || (ref.indexOf("nextearningsdate.com") > 0) || (ref.indexOf("pastearnings.com") > 0) || (ref.indexOf("historicalperatio.com") > 0) || (ref.indexOf("historicalearnings.com") > 0) || (ref.indexOf("webcache.googleusercontent.com") > 0)) { allow = 1; } function ShowTTIPage() { if (allow) { document.write('\n'); } if (allow) { document.write('
\n'); } if (allow) { document.write('| 4/29 - 8:55 AM \; \; | \n'); } if (allow) { document.write('AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer | \n'); } if (allow) { document.write('
| 4/25 - 8:45 AM \; \; | \n'); } if (allow) { document.write('AIM ImmunoTech Announces Release of the Next CEO Corner Segment | \n'); } if (allow) { document.write('
| 4/18 - 8:45 AM \; \; | \n'); } if (allow) { document.write('AIM ImmunoTech Announces Release of the Next CEO Corner Segment | \n'); } if (allow) { document.write('
| 4/15 - 8:55 AM \; \; | \n'); } if (allow) { document.write('AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs | \n'); } if (allow) { document.write('
| 4/11 - 11:00 AM \; \; | \n'); } if (allow) { document.write('AIM ImmunoTech Announces Release of the Next CEO Corner Segment | \n'); } if (allow) { document.write('
| 4/10 - 8:21 AM \; \; | \n'); } if (allow) { document.write('AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer | \n'); } if (allow) { document.write('
| 4/2 - 7:30 AM \; \; | \n'); } if (allow) { document.write('AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update | \n'); } if (allow) { document.write('
| 3/28 - 8:05 AM \; \; | \n'); } if (allow) { document.write('AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference | \n'); } if (allow) { document.write('
| 3/26 - 9:05 AM \; \; | \n'); } if (allow) { document.write('AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast | \n'); } if (allow) { document.write('
| 3/25 - 9:05 AM \; \; | \n'); } if (allow) { document.write('AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research | \n'); } if (allow) { document.write('
| 3/22 - 8:55 AM \; \; | \n'); } if (allow) { document.write('AIM ImmunoTech Announces Release of the Next CEO Corner Segment | \n'); } if (allow) { document.write('
| 3/20 - 9:25 AM \; \; | \n'); } if (allow) { document.write('AIM ImmunoTech Announces Release of the Next CEO Corner Segment | \n'); } if (allow) { document.write('
| 3/15 - 8:45 AM \; \; | \n'); } if (allow) { document.write('AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity | \n'); } if (allow) { document.write('
| 3/7 - 8:45 AM \; \; | \n'); } if (allow) { document.write('AIM ImmunoTech Announces Launch of CEO Corner Platform | \n'); } if (allow) { document.write('
| 2/29 - 8:45 AM \; \; | \n'); } if (allow) { document.write('AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update | \n'); } if (allow) { document.write('
| 2/14 - 8:55 AM \; \; | \n'); } if (allow) { document.write('AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen (rintatolimod) in Combination with AstraZeneca\'s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer | \n'); } if (allow) { document.write('
| 2/8 - 8:50 AM \; \; | \n'); } if (allow) { document.write('AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen for the Treatment of Post-COVID Conditions | \n'); } if (allow) { document.write('
| 1/24 - 9:10 AM \; \; | \n'); } if (allow) { document.write('AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen for the Treatment of Locally Advanced Pancreatic Cancer | \n'); } if (allow) { document.write('
| 1/22 - 8:55 AM \; \; | \n'); } if (allow) { document.write('AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen in Combination with AstraZeneca\'s Imfinzi for the Treatment of Late-Stage Pancreatic Cancer | \n'); } if (allow) { document.write('
| 1/10 - 8:45 AM \; \; | \n'); } if (allow) { document.write('AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen (rintatolimod) in Combination with AstraZeneca\'s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer | \n'); } if (allow) { document.write('
 | |
| more news | \n'); } if (allow) { document.write('\n'); } if (allow) { document.write(' |
If you reached this page'+
' after attempting to place a TickerTech.com product onto your web page, go no further; you must sign up as a'+
' paying client. For pricing information please visit our products page, email '+
' services@tickertech.com, or give us a call at 1-866-515-2082.'+
' '+
'